Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;24(4):190-194.
doi: 10.1080/14670100.2023.2198789. Epub 2023 Apr 24.

Outcomes after revision of Advanced Bionics Clarion 1.2 cochlear implants

Nicholas S Andresen  1 , Lekha V Yesantharao  2 , Stephen P Bowditch  1 , Deepa J Galaiya  1 , Charles C Della Santina  1 , Francis X Creighton  1 , Daniel Q Sun  1
Affiliations

Outcomes after revision of Advanced Bionics Clarion 1.2 cochlear implants

Nicholas S Andresen et al. Cochlear Implants Int. 2023 Jul.

Abstract

Introduction: Cochlear implant reimplantation (CIR) for external processor upgrade or device failure is becoming increasingly common as the population of cochlear implant recipients ages. Patients with Advanced Bionics (AB) Clarion 1.2 cochlear implants may undergo CIR for device age/failure or desired technology upgrade so that they may use newer external processors that have improved connectivity features. The objective of this study was to evaluate audiologic outcomes for patients who were initially implanted with an AB Clarion 1.2 internal device and underwent CIR for technology upgrade or device failure.

Methods: Retrospective chart review was performed at a single academic medical center for patients (pediatric and adult) with an AB Clarion 1.2 internal device who underwent CIR to a later generation AB internal device and had available audiologic data.

Results: Forty-eight individuals with a Clarion 1.2 implant underwent CIR. Pre- and post-CIR speech understanding did not change for AzBio (p-value = 0.11, mean change = 12.1%, 95% CI = -2.9-27.2%), CNCw (p-value = 0.74, mean change = -1%, 95% CI = -10.4-12.4%), or HINT (p-value = 0.12, mean change = 19.9%, 95% CI = -2.6-42.4%) scores. Pure-tone averages improved following CIR (p-value < 0.01, mean change = 4.3 dB, 95% CI = 1.5-7.1 dB).

Conclusions: Revision of AB Clarion 1.2 cochlear implants does not significantly worsen audiologic outcomes and may improve hearing in some individuals, but individual patient-level outcomes are variable.

Keywords: Clarion 1.2; Cochlear implant revision; Cochlear implantation; Technology upgrade.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Box plots displaying pre- and post-CIR AzBio, CNCw, and HINT scores (Panel A) and pure tone averages (Panel B). *=p-value <0.0125.
Figure 2.
Figure 2.
Simple linear regression of pre- and post-CIR AzBio (Panel A), CNCw (Panel B), and HINT (Panel C) scores. The dashed line signifies the x=y line.
See this image and copyright information in PMC

References

    1. Blanchard M, Thierry B, Glynn F, De Lamaze A, Garabédian EN, & Loundon N (2015). Cochlear implant failure and revision surgery in pediatric population. Ann Otol Rhinol Laryngol, 124(3), 227–231. 10.1177/0003489414551931 - DOI - PubMed
    1. Brendel M, Rottmann T, Lenarz T, & Buechner A (2013). Performance of the Harmony™ behind-the-ear processor with the first generation of Advanced Bionics™ implant systems. Cochlear Implants Int, 14(1), 36–44. 10.1179/1754762811Y.0000000032 - DOI - PubMed
    1. Buechner A, Frohne-Buechner C, Gaertner L, Lesinski-Schiedat A, Battmer RD, & Lenarz T (2006). Evaluation of Advanced Bionics high resolution mode. Int J Audiol, 45(7), 407–416. 10.1080/14992020600625155 - DOI - PubMed
    1. Chang YT, Yang HM, Lin YH, Liu SH, & Wu JL (2009). Tone discrimination and speech perception benefit in Mandarin-speaking children fit with HiRes fidelity 120 sound processing. Otol Neurotol, 30(6), 750–757. 10.1097/MAO.0b013e3181b286b2 - DOI - PubMed
    1. Class 2 Device Recall CLARION 1.2, Advanced Bionics implantable cochlear stimulator. (2004). U.S. Food and Drug Administration. Retrieved November 9, 2021 from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRes/res.cfm?id=35399

Publication types